Drägerwerk's CEO Waits for Berlin to Act on EU PFAS Ban — Compliance Risk Mounts

The Quick Take

• Drägerwerk CEO Stefan Dräger is publicly calling on the German government to intervene in the EU PFAS chemical ban debate, citing major operational implications
• PFAS (per- and polyfluoroalkyl substances) are used in medical devices and safety equipment — Drägerwerk's core product lines — making a broad ban an existential product liability issue
• The company believes the German government 'could still intervene' to modify the EU restriction before it takes effect — a sign the regulatory timeline is approaching
• A comprehensive PFAS ban without adequate substitution periods would require expensive reformulation across Drägerwerk's medical and industrial safety product portfolio

Drägerwerk, the German maker of medical devices and safety equipment for industrial and emergency response use, is navigating one of the most consequential regulatory debates in European industrial chemistry: the proposed EU-wide restriction on PFAS (per- and polyfluoroalkyl substances). CEO Stefan Dräger's public call for German government intervention reflects the severity of the operational impact — PFAS are used in seals, coatings, and materials critical to the performance and safety certification of medical ventilators, gas detection equipment, and personal protective equipment, all of which sit in Drägerwerk's core portfolio.

The PFAS regulatory situation in the EU involves a proposed restriction under REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals) that would affect thousands of industrial compounds. Medical device manufacturers and safety equipment makers are lobbying for extended use authorizations and sector-specific exemptions, arguing that no technically viable substitutes currently exist for many applications. Drägerwerk's public stance — asking Berlin to intervene rather than proposing internal substitution timelines — suggests the company has not identified a cost-effective reformulation pathway that preserves product performance.

For investors in Drägerwerk (XETRA: DRW3) and EU-listed industrial and medical device companies, the PFAS regulatory risk is real but diffuse. The outcome depends on the German government's willingness to negotiate sector exemptions at the EU level, and on whether the European Chemicals Agency's timeline allows adequate substitution periods. Companies with heavy PFAS exposure in medical devices — including Drägerwerk, 3M Europe, and various specialty chemical manufacturers — should be monitored for any regulatory filing disclosures on PFAS compliance cost estimates.

Synthesized from 2 sources.